可切除食管鳞癌新辅助同步放化疗加手术对比单纯手术的疗效及安全性<em>Meta分析</em>

doi:10.3760/cma.j.issn.1004-4221.2020.01.005

摘要
图/表
参考文献(15)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的系统评价可切除食管鳞癌新辅助同步放化疗+手术与单纯手术模式的有效性及安全性差异。方法计算机检索Embase、Pubmed、Web of Science、Cochrane library、万方、中国知网、中国生物医学文献数据库等,查找辅助同步放化疗联合手术对比单纯手术治疗可切除食管鳞癌的临床随机对照研究文献。使用Revman 5.3统计软件对生存资料、R0切除率、术后并发症发生率及治疗期间死亡率进行Meta分析。结果最终纳入11个临床随机对照研究文献,共计1450例患者。结果显示新辅助同步放化疗+手术组有更高的2、5年总生存率(RR=1.14,95%CI为1.05~1.23,P=0.00)和2、5年无进展生存率(RR=1.56,95%CI为1.05~2.32,P=0.03);提高了R0切除率(RR=1.10,95%CI为1.05~1.14,P=0.00),术后心律失常发生率也较高(RR=2.45,95%CI为1.37~4.38,P=0.00)。两组术后并发症总发生率和治疗期间死亡率均相近(RR=1.12,95%CI为0.79~1.59,P=0.51和RR=1.78,95%CI为0.90~3.52,P=0.10)。结论可切除食管鳞癌新辅助同步放化疗+手术较单纯手术带来更多生存获益,并未明显增加不良反应发生率,是治疗可切除食管鳞癌的一种可选方案。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	谢瑞霖
	李那
	秦庆伟
	王胜
	赵雪
	覃朝晖
	姚元虎

关键词 ：食管肿瘤/新辅助放化疗法, 食管肿瘤/外科学, 预后, 荟萃分析

Abstract：Objective To systematically evaluate the efficacy and safety between neoadjuvant concurrent chemoradiotherapy followed by surgery and surgery alone in the treatment of resectable esophageal squamous cell carcinoma. Methods Literature review was performed from Embase,PubMed,Web of Science,Cochrane Library,CBM,Wanfang Data,CNKI and Chongqing VIP. The randomized controlled clinical trials of concurrent chemoradiotherapy followed by surgery versus surgery alone in the treatment of resectable esophageal squamous cell carcinoma were retrieved. The meta-analysis of survival data,R0 resection rate,incidences of postoperative complications and peritreatment mortality was conducted by using RevMan 5.3 software. Results A total of 1450 patients from 11 controlled clinical trials were included in this meta-analysis. The results of the meta-analysis showed that concurrent chemoradiotherapy followed by surgery group had significantly higher 2-and 5-year overall survival rate (RR=1.14,95%CI:1.05-1.23,P=0.00) and progression-free survival rate (RR=1.56,95%CI:1.05-2.32,P=0.03).R0 resection rate were also improved in concurrent chemoradiotherapy followed by surgery group (RR=1.10,95%CI:1.05-1.14,P=0.00). Compared with the surgery alone group,the incidence of arrhythmia in the concurrent chemoradiotherapy plus surgery group was significantly higher (RR=2.45,95%CI:1.37-4.38,P=0.00). However,there was no significant difference in the overall incidence of postoperative complications (RR=1.12,95%CI:0.79-1.59,P=0.51) and incidence of peritreatment mortality (RR=1.78, 95%CI:0.90-3.52,P=0.10) between two groups. Conclusion s Neoadjuvant concurrent chemoradiotherapy followed by surgery improves the survival and R0 resection rate over surgery alone among patients with resectable esophageal squamous cell carcinoma, whereas it does not increase the risk of postoperative complications. Consequently,neoadjuvant concurrent chemoradiotherapy followed by surgery is an optimal treatment for patients with resectable esophageal squamous cell carcinoma.

Key words： Esophageal neoplasm/neoadjuvant chemoradiotherapy Esophageal neoplasm/surgery Prognosis Meta-analysis

收稿日期: 2019-04-10

基金资助:江苏省高层次卫生人才“六个一工程”项目(LGY2016041)

通讯作者: 姚元虎,Email:yyhxz@xzhmu.edu.cn

引用本文:

谢瑞霖,李那,秦庆伟等. 可切除食管鳞癌新辅助同步放化疗加手术对比单纯手术的疗效及安全性Meta分析[J]. 中华放射肿瘤学杂志, 2020, 29(1): 22-25.

Xie Ruilin,Li Na,Qin Qingwei et al. Efficacy and safety of neoadjuvant concurrent chemoradiotherapy followed by surgery versus surgery alone in the treatment of resectable esophageal squamous cell carcinoma:a Meta-analysis[J]. Chinese Journal of Radiation Oncology, 2020, 29(1): 22-25.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2020.01.005 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2020/V29/I1/22

[1]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA:a cancer journal for clinicians. 2016,66(2):115-32. DOI:10.3322/caac.21338.
[2]Shapiro J,Van Lanschot JJB,Hulshof M,et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J]. The Lancet Oncology,2015,16(9):1090-1098. DOI:10.1016/S1470-2045(15)00040-6.
[3]Lee JL. A single institutional phase Ⅲ trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma[J]. Ann Oncol,2004,15(6):947-954. DOI:10.1093/annonc/mdh219.
[4]Burmeister BH,Smithers BM,Gebski V,et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus:a randomised controlled phase Ⅲ trial[J]. LancetOncol,2005,6(9):659-668. DOI:10.1016/S1470-2045(05)70288-6.
[5]Natsugoe S,Okumura H,Matsumoto M,et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution[J]. Dis Esophagus,2006,19(6):468-472. DOI:10.1111/j.1442-2050.2006.00615.x.
[6]Yang H,Liu H,Chen Y,et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010):a phase Ⅲ multicenter,randomized,open-label clinical trial[J]. J Clin Oncol,2018,36(27):2796-2803. DOI:10.1200/JCO.2018.79.1483.
[7]Bass GA,Furlong H,O′sullivan KE,et al. Chemoradiotherapy,with adjuvant surgery for local control,confers a durable survival advantage in adenocarcinoma and squamous cell carcinoma of the oesophagus[J]. Eur J Cancer,2014,50(6):1065-1075. DOI:10.1016/j.ejca.2013.12.022.
[8]Lyu J. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma[J]. World J Gastroenterol,2010,16(13):1649. DOI:10.3748/wjg.v16.i13.1649.
[9]彭林,谢天鹏,韩泳涛,等. 术前放化疗与单纯手术治疗食管鳞癌的随机对照研究[J]. 肿瘤,2008(7):620-622. DOI:10.3781/j.i ssn.100-7431.2008.07.018.
Peng L,Xie TP,Han YT,et al. Randomized controlled study of preoperative chemotherapy and simple surgery to treat esophageal squamous cancer[J]. Tumor,2008(7):620-622. DOI:10.3781/j.i ssn.100-7431.2008.07.018.
[10]谭胜,王国祥. 微创术联用术前放化疗对晚期ESCC的治疗效果[J]. 热带医学杂志,2016,16(11):1417-1419,1431. DOI:10.3969/j.issn.1672-3619.2016.11.019.
Tan S,Wang GX. The therapeutic effect of minimally invasive preoperative chemotherapy on advanced ESCC. J Trop Med,2016,16(11):1417-1419,1431. DOI:10.3969/j.issn.1672-3619.2016.11.019.
[11]洪澜,谭程,薛杨,等. 术前放化疗联合微创食管切除术治疗晚期食管鳞癌疗效观察[J]. 山东医药,2016,56(6):50-51. DOI:10.3969/j.issn.1002-266X.2016.06.018.
Hong L,Tan C,Xue Y,et al. Preoperative chemotherapy in combination with minimally invasive esophageal excision to treat the efficacy of late esophageal squamous cancer observation[J]. Sandong Med J,2016,56(6):50-51. DOI:10.3969/j.issn.1002-266X.2016.06.018.
[12]张强,魏凌云,杨清杰,等. 新辅助放化疗并全腔镜手术治疗局部晚期食管鳞癌的临床研究[J]. 临床军医杂志,2014,42(7):688-690,713. DOI:10.3969/j.issn.1671-3826.2014.07.09.
Zhang Q,Wei LY,Yang QJ,et al. Clinical study of neoadjuvant radiotherapy and chemotherapy and full-cavity surgery to treat local late esophageal squamous cancer[J]. Clin J Med Offi,2014,42(7):688-690,713. DOI:10.3969/j.issn.1671-3826.2014.07.09.
[13]田广伟,李楠,李光. 可切除食管鳞癌新辅助放化疗的Meta分析[J]. 中华肿瘤防治杂志,2013,20(16):1279-1283. DOI:10.16073/j.cnki.cjcpt.2013.16.019.
Tian GW,Li N,Li G. Meta Analysis of New Auxiliary Chemotherapy for The Removal of Esophageal Squamous Cancer[J]. Chin J Cancer Prev Treat,2013,20(16):1279-1283. DOI:10.16073/j.cnki.cjcpt.2013.16.019.
[14]Wang DB,Sun ZY,Deng LM,et al. Neoadjuvant chemoradiotherapy improving survival outcomes for esophageal carcinoma:an updated Meta-analysis[J]. Chin Med J (Engl),2016,129(24):2974-2982. DOI:10.4103/0366-6999.195464.
[15]Reynolds JV,Ravi N,Hollywood D,et al. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy[J]. J Thorac Cardiovascul Surg,2006,132(3):549-555. DOI:10.1016/j.jtcvs.2006.05.015.